SPECT/CT versus planar imaging to determine treatment strategy for non-small-cell lung cancer: a cost–effectiveness analysis-Reference-Cited by-同舟云学术

SPECT/CT versus planar imaging to determine treatment strategy for non-small-cell lung cancer: a cost–effectiveness analysis

Published:2022-03 Issue:4 Volume:11 Page:229-241
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:J. Comp. Eff. Res.

Author:

Romsa Jonathan¹,Imhoff Ryan J²^ORCID,Palli Swetha R²,Inculet Richard³,Mehta Sanjay⁴

Affiliation:

1. Department of Medical Imaging, Division of Nuclear Medicine, University of Western Ontario, 800 Commissioners Rd E, London, ON N6A 5W9, Canada

2. CTI Clinical Trial & Consulting Services, 100 E. RiverCenter Blvd, Covington, KY 41011, USA

3. Department of Surgery, Division of Thoracic Surgery, University of Western Ontario, 268 Grosvenor Street, St. Joseph's Hospital Rm. E3-117, London, ON N6A 4V2, Canada

4. Department of Medicine, Respirology Division, London Health Sciences Centre, University of Western Ontario, 800 Commissioners Rd E, London, ON N6A 5W9, Canada

Abstract

Aim: SPECT/CT has been found to improve predicted postoperative forced expiratory volume in one second (ppoFEV 1 ) assessments in patients with non-small-cell lung cancer (NSCLC). Methods: An economic simulation was developed comparing the cost–effectiveness of SPECT/CT versus planar scintigraphy for a US payer. Clinical outcomes and cost data were obtained through review of the published literature. Results: SPECT/CT increased the accuracy ppoFEV 1 assessment, changing the therapeutic decision for 1.3% of nonsurgical patients to a surgical option, while 3.3% of surgical patients shifted to more aggressive procedures. SPECT/CT led to an expected cost of $4694 per life year gained, well below typical thresholds. Conclusion: SPECT/CT resulted in substantially improved health outcomes and was found to be highly cost-effective.

Funder

GE Healthcare

Publisher

Becaris Publishing Limited

Subject

Health Policy

Link

https://becarispublishing.com/doi/pdf/10.2217/cer-2021-0139

Reference58 articles.

1. Cancer Facts & Figures. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf

2. Non-small-cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina JR;Mayo Clin. Proc.,2008

3. Preoperative assessment as a predictor of mortality and morbidity after lung resection;Markos J;Am. Rev. Respir. Dis.,1989

4. Assessment of operative risk in patients undergoing lung resection. Importance of predicted pulmonary function;Kearney DJ;Chest,1994

5. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines;Brunelli A;Chest,2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incremental diagnostic value of SPECT/CT to post-radioiodine therapy planar whole-body scan in patients with papillary thyroid cancer;2023-11-09

2. Technical concepts on blood pool phase SPECT (acquisition, reconstruction);The Quarterly Journal of Nuclear Medicine and Molecular Imaging;2023-08

3. A review on the usage of bone single-photon emission computed tomography/computed tomography in detecting skeletal metastases in the post-COVID-19 era: Is it time to ditch planar and single-photon emission computed tomography only gamma camera systems?;Indian Journal of Nuclear Medicine;2023